Whole-Patient Evaluation vs. Strict-MELD Listing

Medically reviewed by James F. Trotter, MD and Joseph S. Redman, MD, PhD, National Friends Medical Advisory Board · Last reviewed October 1, 2026

Some liver programs list mainly by MELD score; others weigh the whole patient. Learn the difference, who it affects most, and what to ask your team.

Centers vary in how they make listing decisions, especially for patients whose MELD score does not fully capture how sick they are. SRTR, the national transplant registry, says it plainly: each transplant center has its own requirements for choosing candidates, and being turned down at one center does not mean another center will not accept you (SRTR, Getting Listed).

What MELD does, and what it doesn't

Your MELD score is a number from lab tests that estimates how likely you are to die in the next few months without a transplant. Since July 2023, adult candidates have been ranked with MELD 3.0, which uses bilirubin, INR, creatinine, sodium, albumin, and sex (Kim et al., 2021; Hepatology, 2026). You can estimate yours with our MELD calculator.

Two separate decisions happen on the road to transplant:

Listing: each center decides whether, and when, to put you on the national waiting list. This is where center philosophy matters.
Allocation: once you are listed, national OPTN policy decides the order of organ offers, using MELD (or an approved exception score), blood type, and distance from the donor hospital. No center can change that order.

MELD was built to be objective, so the developers of MELD 3.0 left out ascites and encephalopathy, which are harder to measure the same way everywhere (Kim et al., 2021). That is one reason some very sick patients have a low score.

The two approaches

Strict-MELD listing

The MELD 3.0 score is treated as the primary listing gate.
Cleaner, more uniform listing logic — less variance between coordinators.
Harder for patients with liver cancer (HCC), refractory ascites, recurrent encephalopathy, pulmonary hypertension, or severe frailty whose MELD undercounts their illness burden.

Whole-patient evaluation

The team weighs the full clinical picture: other illnesses, frailty, social support, prior decompensations, quality of life, and whether you qualify for a MELD exception.
More forgiving for patients whose MELD doesn't track their true urgency.
Higher team discretion, which means caregiver advocacy plays a bigger role.

Most centers fall somewhere in between. The labels describe a tendency, not a fixed policy.

Why some centers wait for a higher MELD

Strict-MELD programs are not being careless. A landmark national study found that the survival benefit of transplant in the first year is concentrated in sicker patients. At MELD 6 to 11, patients who received a transplant actually had a higher risk of dying in the first year than similar patients who kept waiting, because surgery itself carries risk. The benefit grew as MELD rose (Merion et al., 2005). That study used the original MELD and only one year of follow-up, so it does not settle the question for any one patient — but it explains why many teams are cautious at low scores.

The case for looking at the whole patient is just as real. In one center's study of 294 listed patients, about 22 out of 100 frail patients died or became too sick for transplant within a year, compared with about 10 out of 100 patients who were not frail. Frailty predicted this risk even after accounting for MELD (Lai et al., 2014).

Patients who often benefit from a whole-patient program

Hepatocellular carcinoma (HCC) within Milan criteria, and some tumors just outside it that may be brought within criteria by treatment
Hepatopulmonary syndrome and portopulmonary hypertension
Recurrent hepatic encephalopathy with low MELD
Refractory ascites requiring frequent paracentesis with low MELD
Pediatric candidates (scored with PELD, not MELD) and small-bodied adults, who can have a harder time getting a size-matched liver; research shows sex and body-size gaps remain under MELD 3.0 (Hepatology, 2026)

Several of these conditions can qualify for a MELD exception, where the center asks a national review board to assign a score that better reflects your risk. Whether your center files those requests, and how hard it argues for them, is a big part of "whole-patient" practice. Our aggressive advocacy article explains how to push for one.

If your local center is strict-MELD and you fit one of these profiles, dual listing at a whole-patient program — ideally one in a different donor area — is worth a conversation. National policy allows listing at more than one center, though centers are not required to list patients who are already listed elsewhere (SRTR FAQ for patients). Our dual-listing guide covers the steps.

Questions to ask your transplant team

"At what MELD score do you usually list patients like me?"
"Do you consider frailty, ascites, or encephalopathy when deciding to list, even if my MELD is low?"
"Would I qualify for a MELD exception? Will you file the request?"
"If you won't list me now, what would change your answer, and when will you re-evaluate me?"
"Will you support me if I seek a second opinion or list at another center?"

SRTR notes there is no single report listing every center's current waitlist criteria (SRTR FAQ for patients), so asking directly is the only reliable way to know.

Common misconceptions

"A low MELD means I'm not sick." Not always. MELD leaves out symptoms like ascites and encephalopathy.
"A whole-patient center can move me up the list." No. Once listed, national policy sets offer order. What a center controls is whether you are listed and whether it requests an exception.
"If one center says no, everyone will." SRTR says each center reviews patients individually and has its own criteria.
"Earlier transplant is always better." At very low MELD, transplant can carry more short-term risk than waiting. That is a decision to make with your team.

How the "Transplants low-MELD patients" filter works

The map's "Transplants low-MELD patients" capability filter uses two SRTR figures for each center: the share of patients listed with a MELD of 6–10 who received a transplant within one year, and the same share for patients listed with a MELD of 11–14. We add the two together. Centers whose combined figure is above the median for the current patient-type segment (adult or pediatric) are highlighted. The threshold is recalculated from the current SRTR data every time the map loads — not a fixed percentage — so it self-corrects as the data shifts year over year.

This filter is a starting point for the conversation, not a verdict on a center. A program just below the median may still be the right fit for your specific clinical picture; a program just above it may not. Use this filter to narrow the list, then call the coordinator and ask the questions above. To compare centers in more detail, see median MELD at transplant and the liver transplant criteria overview.

Sources

Educational only. Not medical advice. Your transplant team has the final word.

← Back to the comparison map